Pluripotent Stem Cells to Cure and Study Pulmonary Fibrosis
DOI:
https://doi.org/10.54097/tbz7n229Keywords:
Pulmonary Fibrosis, Pluripotent Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem CellsAbstract
Pulmonary fibrosis, a devastating lung disease characterized by scarring and dysfunction of the lung tissue, lacks effective treatments and a comprehensive understanding of its pathogenesis. Pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), offer a promising approach for both therapeutic interventions and the use of pluripotent stem cells. Pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), offer a promising approach for both therapeutic interventions and disease modeling. These cells can be differentiated into lung-specific cell types, such as alveolar epithelial cells and airway epithelial cells, which can be used to study the mechanisms of pulmonary fibrosis and test potential anti-fibrotic drugs. In vitro models derived from pluripotent stem cells, such as lung organoids and three-dimensional cell cultures, recapitulate the complex cellular and extracellular structures. the complex cellular and extracellular matrix interactions of the lung, providing a more accurate representation of the human disease state than traditional animal models. Furthermore, recent advances in directed differentiation and bioengineering techniques have enabled the generation of lung tissue-like structures that could potentially reduce the risk of lung cancer. Furthermore, recent advances in directed differentiation and bioengineering techniques have enabled the generation of lung tissue-like structures that could potentially be used for regenerative medicine to repair or replace damaged lung tissue in pulmonary fibrosis patients. patients.
Downloads
References
[1] Richeldi L, Collard H R, Jones M G. Idiopathic pulmonary fibrosis[J]. Lancet (London, England), 2017, 389(10082): 1941 -1952.
[2] Koudstaal T, Wijsenbeek M S. Idiopathic pulmonary fibrosis[J]. Presse Medicale (Paris, France: 1983), 2023, 52(3): 104166.
[3] Bayati P, Taherian M, Assarehzadegan M A, et al. Induced Pluripotent Stem-cells Inhibit Experimental Bleomycin-induced Pulmonary Fibrosis through Regulation of the Insulin-like Growth Factor Signaling[J]. Iranian Journal of Allergy, Asthma, and Immunology, 2022, 21(3): 263-272.
[4] Bayati P, Taherian M, Soleimani M, et al. Induced pluripotent stem cells modulate the Wnt pathway in the bleomycin-induced model of idiopathic pulmonary fibrosis[J]. Stem Cell Research & Therapy, 2023, 14(1): 343.
[5] Banerjee E R, Laflamme M A, Papayannopoulou T, et al. Human embryonic stem cells differentiated to lung lineage-specific cells ameliorate pulmonary fibrosis in a xenograft transplant mouse model[J]. PloS One, 2012, 7(3): e33165.
[6] Cui A, Li S, Li Y, et al. Nitric oxide-mediated the therapeutic properties of induced pluripotent stem cell for paraquat-induced acute lung injury[J]. Frontiers in Immunology, 2023, 14: 1136290.
[7] Soh B S, Zheng D, Li Yeo J S, et al. CD166(pos) subpopulation from differentiated human ES and iPS cells support repair of acute lung injury[J]. Molecular Therapy: The Journal of the American Society of Gene Therapy, 2012, 20(12): 2335-2346.
[8] Bueno M, Calyeca J, Khaliullin T, et al. CYB5R3 in type II alveolar epithelial cells protects against lung fibrosis by suppressing TGF-β1 signaling[J]. JCI insight, 2023, 8(5): e161487.
[9] Chong L, Ahmadvand N, Noori A, et al. Injury activated alveolar progenitors (IAAPs): the underdog of lung repair[J]. Cellular and molecular life sciences: CMLS, 2023, 80(6): 145.
[10] Fehrenbach H. Alveolar epithelial type II cells from embryonic stem cells: knights in shining armour?[J]. The European Respiratory Journal, 2012, 39(2): 240-241.
[11] Spitalieri P, Quitadamo M C, Orlandi A, et al. Rescue of murine silica-induced lung injury and fibrosis by human embryonic stem cells[J]. The European Respiratory Journal, 2012, 39(2): 446-457.
[12] Sangiuolo F, Spitalieri P, Quitadamo M, et al. Human embryonic stem cells recover in vivo acute lung inflammation bleomycin-induced[J]. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders,. 2013, 30: 177-185.
[13] Zhou Q, Ye X, Sun R, et al. Differentiation of mouse induced pluripotent stem cells into alveolar epithelial cells in vitro for use in vivo[J]. Stem Cells Translational Medicine, 2014, 3(6): 675-685.
[14] Mitra S, Banerjee E R. Hyperoxia-preconditioned human ESC line KIND1, predominantly differentiated into SP-C+ type-II alveolar epithelial cells, reduces idiopathic pulmonary fibrosis in mice[J]. Proceedings of the Zoological Society, 2023, 76(2): 109-122.
[15] Yan Q, Quan Y, Sun H, et al. A Site-Specific Genetic Modification for Induction of Pluripotency and Subsequent Isolation of Derived Lung Alveolar Epithelial Type II Cells[J]. STEM CELLS, 2014, 32(2): 402-413.
[16] Wu J, Song D, Li Z, et al. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis[J]. Cell Research, 2020, 30(9): 794-809.
[17] Wu J, Zhou X, Tan Y, et al. Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs[J]. Cell Proliferation, 2020, 53(12): e12944.
[18] Gazdhar A, Grad I, Tamò L, et al. The secretome of induced pluripotent stem cells reduces lung fibrosis in part by hepatocyte growth factor[J]. Stem Cell Research & Therapy, 2014, 5(6): 123.
[19] Zhou Y, Zhang Q, Gao Y, et al. Induced pluripotent stem cell-conditioned medium suppresses pulmonary fibroblast-to-myofibroblast differentiation via the inhibition of TGF-β1/Smad pathway[J]. International Journal of Molecular Medicine, 2018, 41(1): 473-484.
[20] Zhou Y, He Z, Gao Y, et al. Induced Pluripotent Stem Cells Inhibit Bleomycin-Induced Pulmonary Fibrosis in Mice through Suppressing TGF-β1/Smad- Mediated Epithelial to Mesenchymal Transition[J]. Frontiers in Pharmacology, 2016, 7: 430.
[21] Zhang L, Wang Y, Wu G, et al. Macrophages: friend or foe in idiopathic pulmonary fibrosis?[J]. Respiratory Research, 2018, 19(1): 170.
[22] Evolving perspectives on innate immune mechanisms of IPF.[J]. Frontiers in Molecular Biosciences, 2021, 8: 676569.
[23] Tamò L, Fytianos K, Caldana F, et al. Interactome Analysis of iPSC Secretome and Its Effect on Macrophages In Vitro[J]. International Journal of Molecular Sciences, 2021, 22(2): 958.
[24] Tamò L, Simillion C, Hibaoui Y, et al. Gene Network Analysis of Interstitial Macrophages After Treatment with Induced Pluripotent Stem Cells Secretome ( iPSC-cm) in the Bleomycin Injured Rat Lung[J]. Stem Cell Reviews and Reports, 2018, 14(3): 412-424.
[25] Zhou Y, Gao Y, Zhang W, et al. Exosomes derived from induced pluripotent stem cells suppress M2-type macrophages during pulmonary fibrosis via miR- 302a-3p/TET1 axis[J]. International Immunopharmacology, 2021, 99: 108075.
[26] Akram K M, Spiteri M A, Forsyth N R. Activin-directed differentiation of human embryonic stem cells differentially modulates alveolar epithelial wound repair via paracrine mechanism[J]. Stem Cell Discovery, 2014, 2014.
[27] How C K, Chien Y, Yang K Y, et al. Induced pluripotent stem cells mediate the release of interferon gamma-induced protein 10 and alleviate bleomycin- induced lung inflammation and fibrosis[J]. Shock (Augusta, Ga.), 2013, 39(3): 261-270.
[28] Montay-Gruel P, Zhu Y, Petit B, et al. Extracellular Vesicles for the Treatment of Radiation-Induced Normal Tissue Toxicity in the Lung[J]. Frontiers in Oncology, 2020, 10: 602763.
[29] Liu Q, Bi Y, Song S, et al. Exosomal miR-17-5p from human embryonic stem cells prevents pulmonary fibrosis by targeting thrombospondin-2[J]. Stem Cell Research & Therapy, 2023, 14(1): 234.
[30] Alvarez-Palomo B, Sanchez-Lopez L I, Moodley Y, et al. Induced pluripotent stem cell-derived lung alveolar epithelial type II cells reduce damage in bleomycin-induced lung fibrosis[J]. Stem Cell Research & Therapy, 2020, 11(1): 213.
[31] Quan Y, Wang Z, Gong L, et al. Exosome miR-371b-5p promotes proliferation of lung alveolar progenitor type II cells by using PTEN to orchestrate the PI3K/ akt signaling[J]. Stem Cell Research & Therapy, 2017, 8.
[32] Hu W, Yang J, Xue J, et al. Secretome of hESC-Derived MSC-like Immune and Matrix Regulatory Cells Mitigate Pulmonary Fibrosis through Antioxidant and Anti-Inflammatory Effects[J]. Biomedicines, 2023, 11(2): 463.
[33] Yang S, Liu P, Gao T, et al. Every road leads to Rome: therapeutic effect and mechanism of the extracellular vesicles of human embryonic stem cell-derived immune and matrix regulatory cells administered to mouse models of pulmonary fibrosis through different routes[J]. immune and matrix regulatory cells administered to mouse models of pulmonary fibrosis through different routes[J]. Stem Cell Research & Therapy, 2022, 13(1): 163.
[34] Shyam R, Reddy L V K, Palaniappan A. Fabrication and characterization techniques of In vitro 3D tissue models[J]. International Journal of Molecular Sciences, 2023, 24(3): 1912.
[35] Chen J, Na F. Organoid technology and applications in lung diseases: models, mechanism research and therapy opportunities [J]. Frontiers in Bioengineering and Biotechnology, 2022, 10: 1066869.
[36] Nikolić M Z, Rawlins E L. Lung organoids and their use to study cell-cell interaction[J]. Current Pathobiology Reports, 2017, 5(2): 223-231.
[37] Gkatzis K, Taghizadeh S, Huh D, et al. Use of three-dimensional organoids and lung-on-a-chip methods to study lung development, regeneration and disease[J]. European Respiratory Journal, 2018, 52(5).
[38] Barkauskas C E, Chung M I, Fioret B, et al. Lung organoids: current uses and future promise[J]. Development (Cambridge, England), 2017, 144(6): 986-997.
[39] Kühl L, Graichen P, Von Daacke N, et al. Human lung organoids-a novel experimental and precision medicine approach[J]. Cells, 2023, 12(16): 2067.
[40] Huang S X L, Islam M N, O'Neill J, et al. Efficient generation of lung and airway epithelial cells from human pluripotent stem cells[J]. Nature Biotechnology, 2014, 32(1): 84-91.
[41] Dye B R, Hill D R, Ferguson M A, et al. In vitro generation of human pluripotent stem cell derived lung organoids[J]. eLife, 2015, 4: e05098.
[42] Wilkinson D C, Alva-Ornelas J A, Sucre J M S, et al. Development of a Three-Dimensional Bioengineering Technology to Generate Lung Tissue for Personalized Disease Modeling[J]. Stem Cells Translational Medicine, 2017, 6(2): 622-633.
[43] Pei R, Feng J, Zhang Y, et al. Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection[J]. Protein & Cell, 2021, 12(9): 717-733.
[44] Gotoh S, Ito I, Nagasaki T, et al. Generation of alveolar epithelial spheroids via isolated progenitor cells from human pluripotent stem cells[J]. Stem Cell Reports, 2014, 3(3): 394-403.
[45] Yamamoto Y, Gotoh S, Korogi Y, et al. Long-term expansion of alveolar stem cells derived from human iPS cells in organoids[J]. Nature Methods, 2017, 14(11): 1097-1106.
[46] Suezawa T, Kanagaki S, Moriguchi K, et al. Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids[J]. Stem Cell Reports, 2021, 16(12): 2973-2987.
[47] Ptasinski V, Monkley S J, Öst K, et al. Modeling fibrotic alveolar transitional cells with pluripotent stem cell-derived alveolar organoids[J]. Life Science Alliance, 2023, 6(8): e202201853.
[48] Kim J H, An G H, Kim J Y, et al. Human pluripotent stem-cell-derived alveolar organoids for modeling pulmonary fibrosis and drug testing[J]. Cell Death Discovery, 2021, 7(1): 48.
[49] Choi S, Choi J, Cheon S, et al. Pulmonary fibrosis model using micro-CT analyzable human PSC-derived alveolar organoids containing alveolar macrophage -like cells[J]. Cell Biology and Toxicology, 2022, 38(4): 557-575.
[50] Magro-Lopez E, Chamorro-Herrero I, Zambrano A. Effects of Hypocalcemic Vitamin D Analogs in the Expression of DNA Damage Induced in Minilungs from hESCs: Implications for Lung Fibrosis[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23(9): 4921.
[51] Hein R F C, Conchola A S, Fine A S, et al. Stable iPSC-derived NKX2-1+ lung bud tip progenitor organoids give rise to airway and alveolar cell types[J]. Development (Cambridge, England), 2022, 149(20): dev200693.
[52] Mou H, Zhao R, Sherwood R, et al. Generation of multipotent lung and airway progenitors from mouse ESCs and patient-specific cystic fibrosis iPSCs[J]. Cell Stem Cell, 2012, 10(4): 385-397.
[53] Miller A J, Hill D R, Nagy M S, et al. In vitro induction and In vivo engraftment of lung bud tip progenitor cells derived from human pluripotent stem cells[J]. . Stem Cell Reports, 2018, 10(1): 101-119.
[54] Dye B R, Dedhia P H, Miller A J, et al. A bioengineered niche promotes in vivo engraftment and maturation of pluripotent stem cell derived human lung organoids[J]. eLife, 2016, 5: e19732.
[55] Dye B R, Youngblood R L, Oakes R S, et al. Human lung organoids develop into adult airway-like structures directed by physico-chemical biomaterial properties[J]. Biomaterials, 2020, 234: 119757.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
